RLF Relief Therapeutics

EQS-News: NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100(TM) (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19

EQS-News: NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100(TM) (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19
EN
13/10/2020

Underlying

RLFRelief Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Relief Therapeutics

Free Trial
RLF Relief Therapeu...

Relief Therapeutics Holding S.A.: 1 director

A director at Relief Therapeutics Holding S.A. sold 11,500 shares at 2.348CHF and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...

RLF RELIEF THERAPEUTICS
06/04/25 June 4, 2025 1 EN
 PRESS RELEASE
Free
RLF Relief Therapeu...

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Con...

Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 18.09.2024 / 07:00 CET/CEST Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024   GENEVA (SEPT. 18, 2024) – (SIX: , OTCQB: , ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has completed dosing in its ...

September 18, 2024 1 EN
 PRESS RELEASE
Free
RLF Relief Therapeu...

Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at...

Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 02.09.2024 / 07:00 CET/CEST Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 GENEVA (SEPT. 2, 2024) – (SIX: , OTCQB: , ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced today that interim data from its clinical trial evaluating PKU GOLIKE® will be presented at the (SSIEM) 2024 Annual Symposium ...

September 2, 2024 1 EN
 PRESS RELEASE
Free
RLF Relief Therapeu...

RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary Gene...

Relief Therapeutics Holding SA / Key word(s): AGMEGM RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting 26.04.2024 / 17:30 CET/CEST RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting of Shareholders Shareholders approved all proposals by a large majority GENEVA (APR. 26, 2024) – (SIX: , OTCQB: , ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announces the results of the extraordinary general ...

April 26, 2024 1 EN
 PRESS RELEASE
Free
RLF Relief Therapeu...

Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual ...

Relief Therapeutics Holding SA / Key word(s): Conference Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference 01.09.2023 / 07:45 CET/CEST Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference GENEVA (SEPT. 1, 2023) – (SIX: , OTCQB: , ) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that Jack Weinstein, chief executive officer, will present a company overview during...

September 1, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch